國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Renal cell carcinomamolecular featur...

Oya, Mototsugu.

Renal cell carcinomamolecular features and treatment updates /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Renal cell carcinomaedited by Mototsugu Oya.
其他題名:	molecular features and treatment updates /
其他作者:	Oya, Mototsugu.
出版者:	Tokyo :Springer Japan :2017.
面頁冊數:	x, 381 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer eBooks
標題:	Renal cell carcinomaMolecular aspects.
電子資源:	http://dx.doi.org/10.1007/978-4-431-55531-5
ISBN:	9784431555315$q(electronic bk.)

Renal cell carcinomamolecular features and treatment updates /
Renal cell carcinomamolecular features and treatment updates /[electronic resource] :edited by Mototsugu Oya. - Tokyo :Springer Japan :2017. - x, 381 p. :ill. (some col.), digital ;24 cm.

Chapter 1 Epidemiology of Renal Cell Carcinoma -- Chapter 2 Hereditary Renal Cell Carcinoma -- Chapter 3 Molecular Genetics of Renal Cell Carcinoma -- Chapter 4 Pathology of Renal Cell Carcinoma -- Chapter 5 Imaging Features of Renal Cell Carcinoma: Differential Diagnosis, Staging and Post-Treatment Evaluation -- Chapter 6 Treatment Overview -- Chapter 7 Natural History and Active Surveillance -- Chapter 8 Surgical Treatment for Renal Cell Carcinoma -- Chapter 9 Predictive and Prognostic Markers in Metastatic Renal Cell Carcinoma -- Chapter 10 Tyrosine-Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, Pazopanib -- Chapter 11 Mammalian Targets of Rapamycin Inhibitors: Temsirolimus, Everolimus -- Chapter 12 Immunotherapy for Renal Cell Carcinoma (RCC): Including Immune Checkpoint Blockade Therapy -- Chapter 13 Treatment for Non-Clear Cell Renal Cell Carcinoma -- Chapter 14 Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy -- Chapter 15 Refractory Mechanisms -- Chapter 16 Optimization of Therapy by Pharmacokinetic: Pharmacodynamic Analyses.

This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma.

ISBN: 9784431555315$q(electronic bk.)

Standard No.: 10.1007/978-4-431-55531-5doiSubjects--Topical Terms:

774351
Renal cell carcinoma
--Molecular aspects.

LC Class. No.: RC280.K5

Dewey Class. No.: 616.99461

Renal cell carcinomamolecular features and treatment updates /
LDR:03441nmm a2200313 a 4500 001 507603
003 DE-He213
005 20170830131400.0
006 m d
007 cr nn 008maaau
008 171030s2017 ja s 0 eng d
020 $a 9784431555315$q(electronic bk.)
020 $a 9784431555308$q(paper)
024 7 $a 10.1007/978-4-431-55531-5 $2 doi
035 $a 978-4-431-55531-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.K5
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99461 $2 23
090 $a RC280.K5 $b R393 2017
245 0 0 $a Renal cell carcinoma $h [electronic resource] : $b molecular features and treatment updates / $c edited by Mototsugu Oya.
260 $a Tokyo : $b Springer Japan : $b Imprint: Springer, $c 2017.
300 $a x, 381 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Chapter 1 Epidemiology of Renal Cell Carcinoma -- Chapter 2 Hereditary Renal Cell Carcinoma -- Chapter 3 Molecular Genetics of Renal Cell Carcinoma -- Chapter 4 Pathology of Renal Cell Carcinoma -- Chapter 5 Imaging Features of Renal Cell Carcinoma: Differential Diagnosis, Staging and Post-Treatment Evaluation -- Chapter 6 Treatment Overview -- Chapter 7 Natural History and Active Surveillance -- Chapter 8 Surgical Treatment for Renal Cell Carcinoma -- Chapter 9 Predictive and Prognostic Markers in Metastatic Renal Cell Carcinoma -- Chapter 10 Tyrosine-Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, Pazopanib -- Chapter 11 Mammalian Targets of Rapamycin Inhibitors: Temsirolimus, Everolimus -- Chapter 12 Immunotherapy for Renal Cell Carcinoma (RCC): Including Immune Checkpoint Blockade Therapy -- Chapter 13 Treatment for Non-Clear Cell Renal Cell Carcinoma -- Chapter 14 Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy -- Chapter 15 Refractory Mechanisms -- Chapter 16 Optimization of Therapy by Pharmacokinetic: Pharmacodynamic Analyses.
520 $a This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma.
650 0 $a Renal cell carcinoma $x Molecular aspects. $3 774351
650 0 $a Renal cell carcinoma $x Treatment. $3 591866
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Oncology. $3 195181
650 2 4 $a Urology. $3 318461
650 2 4 $a Molecular Medicine. $3 273932
700 1 $a Oya, Mototsugu. $3 774350
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-4-431-55531-5
950 $a Medicine (Springer-11650)